BioNTech (NASDAQ:BNTX) CEO Ugur Sahin Sells 32,000 Shares of Stock

Key Points

• BioNTech CEO Ugur Sahin sold 32,000 shares at an average price of $98.12, generating approximately $3.14 million. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, reducing his holdings by 13% to 214,209 shares.
• Sahin has made a series of stock sales throughout September, selling more than 300,000 shares in total over the reported transactions.
• BioNTech shares traded around $98.30, while the company reported weaker-than-expected quarterly results and declining revenue. Despite this, analysts maintain a consensus “Moderate Buy” rating with an average price target of $126.

BioNTech SE Sponsored ADR (NASDAQ:BNTX - Get Free Report) CEO Ugur Sahin sold 32,000 shares of BioNTech stock in a transaction on Wednesday, September 30th. The shares were sold at an average price of $98.12, for a total transaction of $3,139,840.00. Following the transaction, the chief executive officer owned 214,209 shares in the company, valued at approximately $21,018,187.08. This trade represents a 13.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Monday, September 28th, Ugur Sahin sold 34,000 shares of BioNTech stock. The shares were sold at an average price of $98.47, for a total transaction of $3,347,980.00.
• On Friday, September 25th, Ugur Sahin sold 27,000 shares of BioNTech stock. The shares were sold at an average price of $98.69, for a total value of $2,664,630.00.
• On Thursday, September 24th, Ugur Sahin sold 39,000 shares of BioNTech stock. The shares were sold at an average price of $98.99, for a total transaction of $3,860,610.00.
• On Wednesday, September 23rd, Ugur Sahin sold 30,000 shares of BioNTech stock. The stock was sold at an average price of $99.40, for a total value of $2,982,000.00.
• On Tuesday, September 22nd, Ugur Sahin sold 46,000 shares of BioNTech stock. The shares were sold at an average price of $100.72, for a total transaction of $4,633,120.00.
• On Monday, September 21st, Ugur Sahin sold 33,000 shares of BioNTech stock. The shares were sold at an average price of $97.81, for a total value of $3,227,730.00.
• On Friday, September 18th, Ugur Sahin sold 30,000 shares of BioNTech stock. The stock was sold at an average price of $96.22, for a total transaction of $2,886,600.00.
• On Thursday, September 17th, Ugur Sahin sold 34,000 shares of BioNTech stock. The stock was sold at an average price of $98.60, for a total transaction of $3,352,400.00.
• On Wednesday, September 16th, Ugur Sahin sold 15,000 shares of BioNTech stock. The stock was sold at an average price of $96.09, for a total value of $1,441,350.00.
• On Tuesday, September 15th, Ugur Sahin sold 34,000 shares of BioNTech stock. The stock was sold at an average price of $96.49, for a total transaction of $3,280,660.00.

BioNTech Stock Down 0.3%

Shares of NASDAQ BNTX traded down $0.27 during midday trading on Wednesday, reaching $98.30. 807,438 shares of the company's stock traded hands, compared to its average volume of 1,091,041. The company has a market cap of $24.86 billion, a price-to-earnings ratio of -12.55 and a beta of 1.29. The stock's 50 day simple moving average is $98.43 and its 200-day simple moving average is $94.90. The company has a quick ratio of 7.80, a current ratio of 7.85 and a debt-to-equity ratio of 0.01. BioNTech SE Sponsored ADR has a one year low of $79.52 and a one year high of $124.00.

BioNTech (NASDAQ:BNTX - Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.40) by ($0.13). The company had revenue of $122.31 million for the quarter, compared to the consensus estimate of $180.18 million. BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The firm's revenue was down 59.5% compared to the same quarter last year. During the same period last year, the business posted ($1.60) EPS. On average, analysts predict that BioNTech SE Sponsored ADR will post -6.37 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Citigroup dropped their price target on BioNTech from $130.00 to $125.00 and set a "buy" rating on the stock in a research note on Wednesday, August 5th. Weiss Ratings reiterated a "sell (d-)" rating on shares of BioNTech in a research note on Monday, July 6th. UBS Group reissued a "buy" rating on shares of BioNTech in a report on Wednesday, September 16th. Morgan Stanley dropped their price objective on BioNTech from $126.00 to $119.00 and set an "overweight" rating on the stock in a report on Wednesday, July 8th. Finally, Canaccord Genuity Group reduced their price target on shares of BioNTech from $142.00 to $136.00 and set a "buy" rating for the company in a research report on Monday, August 31st. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $126.00.

Institutional Investors Weigh In On BioNTech

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Engineers Gate Manager LP raised its stake in shares of BioNTech by 17.3% in the 2nd quarter. Engineers Gate Manager LP now owns 12,433 shares of the company's stock valued at $1,157,000 after acquiring an additional 1,833 shares during the period. Integrated Wealth Concepts LLC purchased a new position in shares of BioNTech in the 2nd quarter valued at about $39,000. Nykredit A S purchased a new stake in shares of BioNTech in the 2nd quarter valued at approximately $293,000. B. Metzler seel. Sohn & Co. AG raised its stake in BioNTech by 66.7% in the second quarter. B. Metzler seel. Sohn & Co. AG now owns 10,967 shares of the company's stock valued at $1,020,000 after buying an additional 4,390 shares in the last quarter. Finally, Headlands Technologies LLC acquired a new stake in shares of BioNTech during the 2nd quarter worth about $2,520,000. Hedge funds and other institutional investors own 15.52% of the company's stock.

BioNTech Company Profile

BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing therapies and vaccines for cancer and other serious diseases. The company's research platform includes messenger RNA (mRNA), individualized cancer vaccines, immune-modulating therapies, cell therapies, and protein-based therapeutics.

BioNTech is best known for developing the Comirnaty COVID-19 vaccine in collaboration with Pfizer. Comirnaty uses mRNA technology to help stimulate an immune response against COVID-19 and has been distributed in markets around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.